← Back to Search

Local Anesthetic

Exparel Injectable Product for Soft Tissue Mass

Phase 2

Waitlist Available

Research Sponsored by Morristown Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 14 days

Awards & highlights

Study Summary

This trial will compare two types of local anesthetics to see which is more effective in reducing pain after surgery for soft tissue tumors.

Eligible Conditions

Soft Tissue Mass
Musculoskeletal Disorders

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 14 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~14 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Pain Outcomes

Secondary outcome measures

Medication Consumption

Side effects data

From 2020 Phase 3 trial • 60 Patients • NCT03270514

Respiratory Insufficiency

Respiratory Failure

Seizure

Cardiac Arrest

Pneumothorax

Pulmonary Insufficiency

100%

80%

60%

40%

20%

Study treatment Arm

Exparel Injectable Product

Bupivacaine Hydrochloride

Trial Design

2Treatment groups

Experimental Treatment

Group I: Multi-Drug Cocktail GroupExperimental Treatment1 Intervention

70 subjects will receive a Multi-drug Cocktail

Group II: Exparel GroupExperimental Treatment1 Intervention

70 subjects will receive Exparel

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Exparel Injectable Product

2017

Completed Phase 4

~220

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Morristown Medical CenterLead Sponsor

1 Previous Clinical Trials

300 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the FDA cleared Exparel Injectable Product for use?

"There is some data supporting the safety of Exparel Injectable Product, but none yet for efficacy. Thus, it received a score of 2."

Answered by AI

Is recruitment for this research still underway?

"The information available on clinicaltrials.gov does show that this trial is looking for enrolment from patients. This specific trial was originally posted on 27th January 2021 and was last updated on the 27th of April in 2022. The research team conducting this study are hoping to have 140 participants at 1 location."

Answered by AI

Recent research and studies

Clinical Orthopaedics & Related ResearchJournal

Pain Control and Functional Milestones in Total Knee Arthroplasty: Liposomal Bupivacaine Versus Femoral Nerve Block

Yu, Stephen, Alessandra Szulc, Sharon Walton, Joseph Bosco, and Richard Iorio. 2017. “Pain Control and Functional Milestones in Total Knee Arthroplasty: Liposomal Bupivacaine Versus Femoral Nerve Block”. Clinical Orthopaedics & Related Research. Ovid Technologies (Wolters Kluwer Health). doi:10.1007/s11999-016-4740-4.

Pain MedicineJournal

Prescription Opioid Misuse, Abuse, Morbidity, and Mortality: Balancing Effective Pain Management and Safety

Cheatle, Martin D.. 2015. “Prescription Opioid Misuse, Abuse, Morbidity, and Mortality: Balancing Effective Pain Management and Safety”. Pain Medicine. Oxford University Press (OUP). doi:10.1111/pme.12904.

The KneeJournal

A Randomized, Double-blind, Dose-ranging Study Comparing Wound Infiltration of Depofoam Bupivacaine, an Extended-release Liposomal Bupivacaine, to Bupivacaine Hcl for Postsurgical Analgesia in Total Knee Arthroplasty

Bramlett, Kenneth, Erol Onel, Eugene R. Viscusi, and Kevin Jones. 2012. “A Randomized, Double-blind, Dose-ranging Study Comparing Wound Infiltration of Depofoam Bupivacaine, an Extended-release Liposomal Bupivacaine, to Bupivacaine Hcl for Postsurgical Analgesia in Total Knee Arthroplasty”. The Knee. Elsevier BV. doi:10.1016/j.knee.2011.12.004.

The Journal of Clinical PharmacologyJournal